Not a healthcare professional? Visit our Public site

report_adverse_events REPORT ADVERSE EVENT Login Register notification bell

Placeholder

    Contact us REQUEST A REPRESENTATIVE

    Your browser is not supported.

    To view this content, please use one of the following browsers:

    • Microsoft Edge
    • Chrome
    • Safari
    Rezzayo Logo

    Click here to access GB prescribing information or NI prescribing Information

    RESOURCES

    Expert presentations and opinions on REZZAYO® rezafungin

     

    Watch or listen to expert presentations and opinions on REZZAYO®, and access dedicated learning resources or materials for your patients

    Interested in learning more about how REZZAYO® could help in your hospital?
    Request an appointment with a Napp representative

    Request an appointment
    placeholder

    Mechanism of action (MOA)

    Discover the benefits of REZZAYO® mechanism of action

    VIDEO

     

    REZZAYO® rezafungin budget impact summary

    REZZAYO® rezafungin budget impact summary

    Calculate any potential cost saving that could be achieved by switching your patients from their current treatment.

    CALCULATOR

    REZZAYO® rezafungin budget impact summary

    REZZAYO® Formulary Pack

    This formulary pack contains key data for how REZZAYO®, as the first once-weekly echinocandin, can potentially support the treatment of invasive candidiasis 

    PDF

      Reporting adverse events

      Adverse events should be reported. Reporting forms and information can be found at http://yellowcard.mhra.gov.uk/.

      Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyUKandROI@mundipharma.com.

      ®: REZZAYO is a Registered Trademark of Cidara Therapeutics, Inc., used under license